MedTrace Logo

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT05158023 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2024-04-26

No results posted yet for this study

Summary

Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will have 5 treatment arms (4 active and 1 placebo).

Conditions

Interventions

DRUG

Placebo Comparator

Sterile solution for subcutaneous injection

BIOLOGICAL

ASLAN004

Sterile solution for subcutaneous injection

BIOLOGICAL

ASLAN004

Sterile solution for subcutaneous injection

BIOLOGICAL

ASLAN004

Sterile solution for subcutaneous injection

BIOLOGICAL

ASLAN004

Sterile solution for subcutaneous injection

Sponsors & Collaborators

  • ASLAN Pharmaceuticals

    lead OTHER

Principal Investigators

  • Chief Medical Officer · ASLAN Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2023-06-13
Completion
2023-09-05
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Dominican Republic
  • India
  • New Zealand
  • Poland
  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05158023 on ClinicalTrials.gov